Based in Toronto, Ontario, Xagenic is a privately held molecular diagnostics company developing a fully-automated molecular diagnostic platform that will enable lab-free testing with a time-to-result of 20 minutes. The company is developing a menu of infectious disease tests that will have a positive impact on patient care and reduce health care costs. The company is supported by private investors, including BDC Capital, Domain Associates, CTI Life Sciences Fund, and the Ontario Capital Growth Corporation. Xagenic recently received the Frost & Sullivan 2014 Point‑of‑Care Diagnostics New Product Innovation Leadership Award.
Today in funding: Introhive, Fulcrum Capital Partners, Xagenic, and Canadian Media Fund